Navigation Links
Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success

Huge clinical development program of first-in-class CB1 antagonist rimonabant to show benefits beyond weight reduction and avoid image as life-style drug

BARCELONA, Spain | March 08, 2007 | The Business Intelligence firm La Merie S.L. reported today that Sanofi-Aventis’ first-in-class CB1 antagonist Acomplia (rimonabant) has at least five competitors in clinical stages up to phase III and many more in earlier phases of R&D. While Acomplia received EU approval in June 2006, the FDA requested more time to review the file. Acomplia is indicated for the treatment of patients with obesity or overweight plus cardiometabolic risk factors and achieved EU sales of € 31 mln in its first months in selected markets. However, some countries such as Germany consider Acomplia as a non-reimbursable life-style drug. Sanofi-Aventis is undertaking a huge clinical program to profile Acomplia in additional populations such as in type 2 diabetes (1st line), insulinized patients, dyslipidemia or atherosclerosis. Another field of potential use of CB1 antagonists lies in neuroscience, such as addiction and cognitive disorders. These results and more were found in a search conducted by La Merie Business Intelligence. The competitor analysis of CB1 antagonists can be acquired at www.pipelinereview.com, La Merie’s News Center and Online Store.

Rimonabant has been studied in more than 6,000 patients. Results of the RIO-LIPIDS study showed that a one-year treatment of overweight and obese patients with abnormal lipid levels with once daily rimonabant significantly reduced body weigth by an average of 6.9 kg in comparison to a loss of 1.5 kg in the placebo group. More importantly, it improved a range of cardiometabolic risk factors that may contribute to type 2 diabetes and heart disease. Results of a two-year treatment with rimonabant in the RIO- North America study evidenced sustained effects on waist circumference, body weight and cardiometabolic risk factors. Mechanism-based adverse effects associated with CB1 receptor antagonists have not been reported. Results of the SERENADE trial published in December 2006 showed that patients with type 2 diabetes not currently treated with anti-diabetic medication experienced significant improvements in glucose control and weight as well as in HDL cholesterol and triglycerides. Importantly, about 57 % of the improvements in HbA1C were independent of the weight loss achieved.

The mechanism of action of CB1 antagonists still is not yet fully understood. Data indicate a loss of appetite as well as an increase in metabolic rate and a loss of fat mass. In addition, it has been shown that cannabinoid antagonists can prevent drug reinstatement with cocaine, alcohol and nicotine. Sanofi-Aventis had studied rimonabant as an aid to smoking cessation and submitted an NDA based on studies for up to one year in over 6,500 smokers. However, the FDA issued a non-approvable letter for this indication. Studies with other molecules are ongoing to explore the utility of CB1 antagonist in the neuroscience field.

About La Merie

La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com.

About PipelineReview.com

PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence focused on Research and Development in the Biopharmaceutical Industry. Visitors of PipelineReview.com will find R&D relevant press releases and can receive selected R&D news from one or more of the site’s News Channels. A free R&D Newletter conveniently brings via e-mail a daily selection of the most interesting news from biopharmaceutical R&D. For more information visit PipelineReview.com.

SOURCE: La Merie Business Intelligence

Jorge Márquez C/Casp 33 B 4º 2ª. 08010 Barcelona Tel + 34 93 342 91 97 Fax + 93 342 91 98 eMail: jorge.marquez@lamerie.com Online Store: www.pipelinereview.com. http://www.lamerie.com


'"/>




Related medicine technology :

1. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
2. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
3. New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People
4. New Data Confirm That Use of Levemir Can Limit Weight Gain
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Choosing Lab Quality Management Software
7. Optimizing Quality Control Data Management
8. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
9. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
10. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
11. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb.8, 2016 Aesthetic Devices - Medical Devices ... sector report, "Aesthetic Devices - Medical Devices Pipeline Assessment, ... pipeline stage. This report is prepared ... research by GlobalData,s team of industry experts. *Note: ... altered based on the availability and relevance of data ...
(Date:2/8/2016)... 2016 CBG Technologies, a U.S. company, ... Recycling Systems, specifically designed for precision parts cleaning. ... and existing vapor degreasers, parts washers and ultrasonic ... continuous recycling and recovers 100% of the solvent ... --> Precision parts manufacturers benefit from this ...
(Date:2/8/2016)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... and year-end 2015 results after the Nasdaq market closes ... a live conference call and webcast to discuss its ... February 11, 2016 at 4:30 p.m. Eastern Time (1:30 ... http://www.neurocrine.com . --> Participants can access ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER TOLEDO has published a ... a basic understanding of the techniques they use so they can more easily ... reduce waste and rework to create a leaner overall lab experience. , ...
(Date:2/9/2016)... California (PRWEB) , ... February 09, 2016 , ... i2i ... one of the highest preliminary data vendors in the latest KLAS report, Population Health ... i2i has led the developing market for population health management (PHM). The latest ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... with BASF Human Nutrition into the Food & Beverage and ... been BASF’s channel partner throughout Canada and USA geographies east of the Rocky ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton Engineering , powered ... and flow wrapped products at WestPack 2015, February 9-11, in Anaheim, California. This ... to semi-automatic or fully-automatic case packing with a small footprint, rugged, highly flexible, ...
(Date:2/8/2016)... Venice, FL (PRWEB) , ... February 08, 2016 ... ... their new community enrichment program serving the greater Venice, FL area, has initiated ... died tragically in a car accident just four days after Christmas. To support ...
Breaking Medicine News(10 mins):